Royalty Pharma Management
Management criteria checks 2/4
Royalty Pharma's CEO is Pablo Legorreta, appointed in Jan 1996, has a tenure of 28.67 years. directly owns 0.82% of the company’s shares, worth €122.64M. The average tenure of the management team and the board of directors is 1.9 years and 4.3 years respectively.
Key information
Pablo Legorreta
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 28.7yrs |
| CEO ownership | 0.8% |
| Management average tenure | 1.9yrs |
| Board average tenure | 4.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$673m |
| Mar 31 2024 | n/a | n/a | US$799m |
| Dec 31 2023 | n/a | n/a | US$1b |
| Sep 30 2023 | n/a | n/a | US$184m |
| Jun 30 2023 | n/a | n/a | US$255m |
| Mar 31 2023 | n/a | n/a | US$332m |
| Dec 31 2022 | n/a | n/a | US$43m |
| Sep 30 2022 | n/a | n/a | US$507m |
| Jun 30 2022 | n/a | n/a | US$466m |
| Mar 31 2022 | n/a | n/a | US$602m |
| Dec 31 2021 | US$50m | US$8m | US$620m |
| Sep 30 2021 | n/a | n/a | US$783m |
| Jun 30 2021 | n/a | n/a | US$972m |
| Mar 31 2021 | n/a | n/a | US$493m |
| Dec 31 2020 | US$56m | n/a | US$495m |
| Sep 30 2020 | n/a | n/a | US$2b |
| Jun 30 2020 | n/a | n/a | US$2b |
| Mar 31 2020 | n/a | n/a | US$2b |
| Dec 31 2019 | US$29m | n/a | US$2b |
Compensation vs Market: Insufficient data to establish whether Pablo's total compensation is reasonable compared to companies of similar size in the German market.
Compensation vs Earnings: Pablo's compensation has been consistent with company performance over the past year.
CEO
Pablo Legorreta (60 yo)
28.7yrs
Tenure
Mr. Pablo Gerardo Legorreta serves as Chairman of the Board at ProKidney Corp. He is a Co-Founder & Director of Sequel Med Tech, LLC. He serves as the Chief Executive Officer and Co-Founder at RP Managemen...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 28.7yrs | no data | 0.82% $ 122.6m | |
| Executive VP & CFO | no data | US$4.56m | 0.19% $ 28.1m | |
| Executive VP of Investments & Chief Legal Officer | 1.9yrs | US$4.56m | 0.24% $ 36.0m | |
| Vice Chairman & Executive VP | 4.4yrs | US$4.56m | 0.083% $ 12.4m | |
| Executive Vice President of Research & Investments | 3.8yrs | US$4.56m | 0.015% $ 2.2m | |
| Executive Vice President of Investments & General Counsel | 1.9yrs | no data | no data | |
| Executive Vice President of Investments | 1.4yrs | no data | no data | |
| Senior VP & Chief Accounting Officer | no data | no data | no data | |
| Senior VP & Chief Technology Officer | less than a year | no data | no data | |
| Executive VP of Investments & Chief Scientific Officer | 3.8yrs | US$3.40m | no data | |
| Senior VP and Head of Investor Relations & Communications | no data | no data | no data | |
| Executive VP & Head of Human Capital | less than a year | no data | no data |
1.9yrs
Average Tenure
55yo
Average Age
Experienced Management: RPD's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 28.7yrs | no data | 0.82% $ 122.6m | |
| Independent Director | 2.3yrs | US$389.77k | 0.0037% $ 548.4k | |
| Independent Director | 4.2yrs | US$389.77k | 0.0082% $ 1.2m | |
| Independent Director | 4.3yrs | US$389.77k | 0.014% $ 2.2m | |
| Lead Independent Director | 4.2yrs | US$389.77k | 0.023% $ 3.4m | |
| Independent Director | 4.3yrs | US$389.77k | 0.014% $ 2.2m | |
| Independent Director | 4.3yrs | US$389.77k | 0.011% $ 1.6m | |
| Independent Director | 4.3yrs | US$389.77k | 0.0076% $ 1.1m |
4.3yrs
Average Tenure
65.5yo
Average Age
Experienced Board: RPD's board of directors are considered experienced (4.3 years average tenure).